Alba Therapeutics

Founded in 2004 and headquartered in Baltimore, US, Alba Therapeutics develops treatments targeting autoimmune disorders related to the gastrointestinal tract.Alba Therapeutics focuses on developing innovative therapies aimed at treating diseases related to the gastrointestinal tract, with an emphasis on conditions such as celiac disease and other autoimmune disorders. Their primary product, a proprietary formulation of a glutenase enzyme, aims to mitigate the effects of gluten consumption in individuals with celiac disease by breaking down gluten proteins, thus providing relief from gastrointestinal symptoms. This product was specifically designed for patients who are sensitive to gluten and require alternative management options beyond strict dietary restrictions. The company targets healthcare providers, gastroenterologists, and patients within the United States and selected international markets, including Europe and Canada.Alba Therapeutics generates revenue primarily through direct sales of their flagship therapy and potential partnerships with healthcare providers and institutions. The company structures transactions based on a B2B model, where healthcare providers may purchase the glutenase enzyme through established distribution channels. Pricing structures, while not publicly detailed, vary based on the volume of purchase and contractual agreements with healthcare facilities. The company also explores collaborations that may involve licensing agreements or co-development partnerships for further product development. The company is targeting expansion into international markets, with a focus on Europe and Canada, aiming to establish a presence by the end of 2024. Their strategy includes increasing collaboration with healthcare providers to enhance product accessibility and integration.

1. Series A

   Aug 24, 2005

   Amount

   $30M

   Investors

   Locked